

**69**

7. The method of claim 5, wherein an inhibitor of CYP2C19 is administered to the human patient and the inhibitor of CYP2C19 is chloramphenicol, cimetidine, felbamate, fluoxetine, fluvoxamine, indomethacin, ketoconazole, lansoprazole, modafinil, omeprazole, oxcarbazepine, 5  
probenicid, ticlopidine, or topiramate.

**70**

8. The method of claim 5, wherein an inducer of CYP2C19 is administered to the human patient and the inducer of CYP2C19 is carbamazepine, norethindrone, prednisone, or rifampicin.

\* \* \* \* \*